We are a biotech company dedicated to developing next-generation CAR-T cell therapies for both hematologic malignancies and solid tumors. Our platform integrates cutting-edge new target discovery techniques with innovative delivery strategies to maximize safety, efficacy, and patient benefit. By combining deep immunology expertise with precision bioengineering, we aim to overcome the most pressing limitations of current cellular therapies such as insufficient efficacy, limited safety, and poor persistence.